Gift Cards, Urinalysis, and the Only Proven Tool for Meth: Why Contingency Management Is Finally Getting Its Due

The argument against contingency management has always been moral before it was scientific. The objection is intuitive: you are paying people to stop using drugs. That sounds like rewarding behavior that should be intrinsically motivated. That sounds like you’re enabling the wrong thing, or cheapening recovery, or creating perverse incentives. The argument feels coherent until you ask the one question that undoes it: compared to what?

Compared to nothing — which is what most people with methamphetamine use disorder in this country currently receive — contingency management produces meaningfully better outcomes. It reduces stimulant-positive urine tests. It improves treatment retention. It does not produce dependency or withdrawal. It doesn’t cause side effects. In the APA Monitor’s coverage of the intervention’s recent momentum, clinical researchers are specific: across the evidence base, CM is the most effective intervention available for stimulant use disorder, and it works for cocaine as well as methamphetamine, and it does so consistently enough that SAMHSA has formalized guidance around it.

The structure of how it works is worth understanding if you’re a provider or a navigator. A patient in a CM program comes to a clinic for a urinalysis on a scheduled basis — usually two to three times a week in the intensive phase. A negative result earns a small reward, typically a gift card to a retail store. The reward escalates slightly with each consecutive negative result. A positive result or a missed appointment resets the escalation (though not to zero in most protocols). Federal rules under the current CMS advisory cap total annual incentives at $750 per patient. In California’s Recovery Incentives program, the most studied version in the Medicaid context, patients earn an average of around $550 across the treatment period.

The $750 cap matters because it constrains program design in ways that affect efficacy. Higher incentive values produce better outcomes in the research literature — not because people are more mercenary at higher dollar amounts, but because the reward signal needs to be meaningful enough to compete with a drug whose acute reward is substantial. The cap was set by the Biden administration in January 2025 after SAMHSA issued a revised advisory, raising the prior $75-per-incentive limit. It’s progress. It’s also lower than what the evidence base suggests would be optimal.

California’s program faces a deadline: by the end of 2026, the state’s Medicaid director must demonstrate the Recovery Incentives program’s value convincingly enough to justify continued federal funding. The data is encouraging but the political climate for Medicaid expansion programs is not. If California’s waiver is not renewed, the most data-rich CM program in the country winds down, and the case for other states to pursue waivers weakens accordingly.

For treatment providers and case managers in Arizona — where AHCCCS does not yet have a CM waiver — the practical path right now is sliding-scale access at programs that fund incentives through grant money or private funding, and advocacy for AHCCCS to pursue a Section 1115 waiver of its own. That advocacy is exactly what the state’s opioid settlement dollars, properly deployed, could support.

More on stimulant treatment options at /newsroom/substances/stimulants.